TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to ...

Dr. Charles Olomofe, visiting assistant professor of Public Health, had an abstract accepted for poster presentation at the annual conference of the Society for Epidemiologic Research (SER), in Boston ...

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...

Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades.

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

Four abstracts accepted for poster presentation highlight Cogent’s expertise in pioneering best-in-class therapeuticsWALTHAM, ...